Sorafenib
- PDF / 123,005 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 86 Downloads / 145 Views
1
S
Splenic infarction: case report A 69-year-old woman developed splenic infarction during treatment with sorafenib for hepatocellular carcinoma. The woman presented with left upper quadrant pain 2 months after sorafenib administration. She had received two cycles of floxuridine and oral sorafenib 400mg twice daily for intrahepatic metastases. During the treatments, she had developed itching of both palms and abdominal pain. Endoscopic investigations had revealed acute gastromucosal lesions. She started receiving sucralfate and the abdominal pain improved; however, the abdominal pain returned several days later. She reported a sudden onset of dull, left upper quadrant abdominal pain. Sorafenib was discontinued, and the woman’s symptoms gradually improved. CT scan revealed a wedgeshaped opacity in the spleen, suggestive of an acute infarction. She received further chemotherapy with floxuridine. Sorafenib was re-administered at discharge; however, she experienced a second attack of left upper quadrant pain, and it was discontinued. CT scan performed at 1-month follow-up revealed another wedge-shaped lesion in the spleen. One month later, the infarction size had decreased. Kim SO, et al. Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient. World Journal of Gastroenterology 17: 267-270, No. 2, 14 Jan 2011. Available from: URL: http://dx.doi.org/10.3748/wjg.v17.i2.267 - South 803056008 Korea
0114-9954/10/1357-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 25 Jun 2011 No. 1357
Data Loading...
